PT  - JOURNAL ARTICLE
AU  - Scuccimarri, Rosie
AU  - Sutton, Evelyn
AU  - Fitzcharles, Mary-Ann
TI  - Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic
AID  - 10.3899/jrheum.200369
DP  - 2020 Apr 02
TA  - The Journal of Rheumatology
PG  - jrheum.200369
4099  - http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.short
4100  - http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.full
AB  - Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].